Literature DB >> 8763400

Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs.

R S Vander Heide1, K A Reimer.   

Abstract

OBJECTIVES: The concept of lethal reperfusion injury in ischemic myocardium has been the subject of controversy. Adenosine administered during reperfusion has been reported to limit lethal reperfusion injury in several studies. On the contrary, it has been reported that cardioprotection may not be achieved with adenosine alone but may occur if adenosine is co-administered with lidocaine. Still other investigators have reported no beneficial effect of adenosine, given with or without lidocaine. If the positive reports are reproducible, they are important both because they provide evidence for the existence of reperfusion injury and establish a rationale for preventing it. Thus, the present study was done to determine if adenosine could limit lethal reperfusion injury in a canine model of regional myocardial ischemia and reperfusion, carefully controlled for baseline predictors of infarct size.
METHODS: Dogs (n = 37) of either sex were subjected to 90 min of coronary occlusion followed by 3 h of reperfusion. Two groups of dogs received adenosine (150 micrograms/kg/min) intravenously for 155 min starting 5 min prior to the reperfusion. One treated group received adenosine only and a second group received adenosine plus lidocaine (2 mg/kg). Control dogs received a saline infusion. After 3 h of reflow, hearts were excised and infarct size was measured and expressed as a percentage of the ischemic area at risk (AAR). To control for variation in infarct size due to variation in collateral blood flow (CBF), infarct size among groups was compared using ANCOVA, using CBF as the independent variable and infarct size as the dependent variable.
RESULTS: Transmural collateral blood flow and AAR were not significantly different between any of the groups. Mean infarct size (adjusted by ANCOVA) in control dogs (n = 9) was 38.1 +/- 5.3% of the AAR. Neither adenosine (n = 9) nor adenosine plus lidocaine (n = 7) significantly limited infarct size (35.6 +/- 5.6% AAR and 38.1 +/- 7.7% AAR, respectively; both P = NS).
CONCLUSIONS: Intravenous adenosine therapy (150 micrograms/kg/min) during reperfusion, whether administered alone or in dogs previously treated with lidocaine, did not limit infarct size after 90 min of regional ischemia in canine myocardium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763400     DOI: 10.1016/0008-6363(95)00235-9

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  17 in total

1.  Lethal Reperfusion Injury: Does It Exist and Does It Matter?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

Review 2.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 3.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia.

Authors:  G P Matherne; J Linden; A M Byford; N S Gauthier; J P Headrick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 5.  Cardioprotection and myocardial reperfusion: pitfalls to clinical application.

Authors:  Richard S Vander Heide; Charles Steenbergen
Journal:  Circ Res       Date:  2013-08-02       Impact factor: 17.367

6.  Effects of postconditioning with N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine in isolated rat hearts.

Authors:  Joon Hong Kim; Joon Kim; Yong-Hyeon Park; Kook Jin Cheun; Young-Ho Jang
Journal:  Korean J Anesthesiol       Date:  2010-03-29

Review 7.  Adenosine and cardioprotection during reperfusion--an overview.

Authors:  Martín Donato; Ricardo J Gelpi
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

Review 8.  Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects.

Authors:  Francisco Villarreal; Scott Zimmermann; Lala Makhsudova; Annika C Montag; Mark D Erion; David A Bullough; Bruce R Ito
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

9.  AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts.

Authors:  Yanping Liu; Xiulan Yang; Xi-Ming Yang; Sheree Walker; Karina Förster; Michael V Cohen; Thomas Krieg; James M Downey
Journal:  Basic Res Cardiol       Date:  2010-01       Impact factor: 17.165

10.  Ischaemic preconditioning and postconditioning do not affect adenosine A(1) and A (2A) receptor sensitivity.

Authors:  Niels P Riksen; Abigail Wynne; Derek M Yellon; Derek J Hausenloy
Journal:  Cardiovasc Drugs Ther       Date:  2009-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.